Ammonium Lactate Lotion, 12%*
Quinosone by
Drug Labeling and Warnings
Quinosone by is a Prescription medication manufactured, distributed, or labeled by V2 Pharma, LLC, Taro Pharmaceuticals Inc., Perrigo New York Inc. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
QUINOSONE- mometasone furoate and ammonium lactate
V2 Pharma, LLC
----------
Ammonium
Lactate
Lotion, 12%*
DESCRIPTION
*Ammonium lactate equivalent to 12% lactic acid, cetyl alcohol, glycerin, glyceryl monostearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methylparaben, polyoxyethylene 100 stearate, polyoxyl 40 stearate, propylene glycol, propylparaben, purified water, and for pH adjustment: lactic acid. Lactic acid is a racemic mixture of 2-hydroxypropanoic acid and has the following structural formula:
CLINICAL PHARMACOLOGY
Lactic acid is an alpha-hydroxy acid. It is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum. In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion. The mechanism(s) by which this is accomplished is not yet known. An in vitro study of percutaneous absorption of Ammonium Lactate Lotion using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.
INDICATIONS AND USAGE
Ammonium lactate lotion is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.
CONTRAINDICATIONS
Ammonium Lactate Lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.
WARNING
Sun exposure to areas of the skin treated with Ammonium Lactate Lotion, 12% should be minimized or avoided (see PRECAUTIONS section). The use of Ammonium Lactate Lotion should be discontinued if hypersensitivity is observed.
Sun exposure to areas of the skin treated with Ammonium Lactate Lotion, 12% should be minimized or avoided (see PRECAUTIONS). The use of Ammonium Lactate Lotion should be discontinued if hypersensitivity is observed.
PRECAUTIONS
General
For external use only. Stinging or burning may occur when applied to skin with fissures, erosions or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation. The potential for post-inflammatory hypo- or hyperpigmentation has not been studied.
Information for Patients
Patients using Ammonium Lactate Lotion, 12% should receive the following information and instructions:
- This medication is to be used as directed by the physician, and should not be used for any disorder other than for which it was prescribed. It is for external use only. Avoid contact with eyes, lips, or mucous membranes.
- Patients should minimize or avoid use of this product on areas of the skin that may be exposed to natural or artificial sunlight, including the face. If sun exposure is unavoidable, clothing should be worn to protect the skin.
- This medication may cause transient stinging or burning when applied to skin with fissures, erosions, or abrasions (for example, after shaving the legs).
- If the skin condition worsens with treatment, the medication should be promptly discontinued.
Carcinogenesis, Mutagenesis, Impairment of Fertility
The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation. The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse in vivo micronucleus assay, both of which were negative. In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or post-natal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m2/day), approximately 0.4 times the human topical dose.
Pregnancy
Teratogenic effects
Pregnancy Category B
Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose respectively (600 mg/kg/day, corresponding to 3600 mg/m2/day in the rat and 7200 mg/m2/day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ammonium lactate lotion should be used during pregnancy only if clearly needed.
Nursing Mothers
Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when ammonium lactate lotion is administered to a nursing woman.
Pediatric Use
Safety and effectiveness of ammonium lactate lotion have been demonstrated in infants and children. No unusual toxic effects were reported.
Geriatric Use
Clinical studies of ammonium lactate lotion 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.
ADVERSE REACTIONS
The most frequent adverse experiences in patients with xerosis are transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness and hyperpigmentation.
Due to the more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).
OVERDOSAGE
The oral administration of ammonium lactate lotion to rats and mice showed this drug to be practically non-toxic (LD50>15 mL/kg).
DOSAGE AND ADMINISTRATION
Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.
Mfd. by:
Taro Pharmaceuticals Inc.
Brampton, Ontario, Canada L6T 1C1
Dist. by:
Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, NY 10532
Revised: March 2013
PRINCIPAL DISPLAY PANEL - 225 g Bottle Label
PULL HERE
225 g
NDC: 51672-1300-5
Ammonium
Lactate
Lotion, 12%*
CONTAINS: *Ammonium lactate
equivalent to 12% lactic acid, cetyl
alcohol, glycerin, glyceryl monostearate,
laureth-4, light mineral oil, magnesium
aluminum silicate, methylcellulose,
methylparaben, polyoxyethylene 100
stearate, polyoxyl 40 stearate, propylene
glycol, propylparaben, purified water, and
for pH adjustment: lactic acid.
For Dermatologic Use Only.
Not for Ophthalmic, Oral or
Intravaginal Use.
See package insert for full prescribing
information.
Store at controlled room temperature
20°-25°C (68°-77°F).
For lot number and expiry date see bottle.
Mfd. by: Taro Pharmaceuticals Inc.
Brampton, Ontario, Canada L6T 1C1
Dist by: Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, NY 10532
PK-3119-2 0313-2
Rx only
TARO
1 INDICATIONS AND USAGE
Mometasone furoate cream 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients ≥ 2 years of age. (1)
2 DOSAGE AND ADMINISTRATION
Brief instructions:
- Apply a thin film to the affected skin areas once daily. (2)
- Discontinue therapy when control is achieved. (2)
- If no improvement is seen within 2 weeks, reassess diagnosis. (2)
- Do not use with occlusive dressings unless directed by a physician. (2)
Detailed description:
Apply a thin film of mometasone furoate cream 0.1% to the affected skin areas once daily. Mometasone furoate cream 0.1% may be used in pediatric patients 2 years of age or older. Since safety and efficacy of mometasone furoate cream 0.1% have not been established in pediatric patients below 2 years of age; use in this age group is not recommended [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. [see Warnings and Precautions (5.1)].
Do not use mometasone furoate cream 0.1% with occlusive dressings unless directed by a physician. Do not apply mometasone furoate cream 0.1% in the diaper area if the patient still requires diapers or plastic pants, as these garments may constitute occlusive dressing.
Avoid contact with eyes. Wash hands after each application. Avoid use on the face, groin, or axillae.
Mometasone furoate cream 0.1% is for topical use only. It is not for oral, ophthalmic, or intravaginal use.
3 DOSAGE FORMS AND STRENGTHS
Cream, 0.1%. Each gram of mometasone furoate cream 0.1% contains 1 mg of mometasone furoate in a white to off-white smooth and homogenous cream base.
4 CONTRAINDICATIONS
Mometasone furoate cream 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.
5 WARNINGS AND PRECAUTIONS
Reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment, Cushing's syndrome, and hyperglycemia may occur due to systemic absorption. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. Modify use should HPA axis suppression develop. (5.1, 8.4)
Pediatric patients may be more susceptible to systemic toxicity. (5.1, 8.4)
May increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist. (5.2)
6 ADVERSE REACTIONS
Most common adverse reactions are: burning, pruritus, and skin atrophy. (6)
To report SUSPECTED ADVERSE REACTIONS, contact G&W Laboratories, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In controlled clinical trials involving 319 subjects, the incidence of adverse reactions associated with the use of mometasone furoate cream 0.1% was 1.6%. Reported reactions included burning, pruritus, and skin atrophy. Reports of rosacea associated with the use of mometasone furoate cream 0.1% have also been received. In controlled clinical trials (n=74) involving pediatric subjects 2 to 12 years of age, the incidence of adverse experiences associated with the use of mometasone furoate cream 0.1% was approximately 7%. Reported reactions included stinging, pruritus, and furunculosis.
The following adverse reactions were reported to be possibly or probably related to treatment with mometasone furoate cream 0.1% during clinical trials in 4% of 182 pediatric subjects 6 months to 2 years of age: decreased glucocorticoid levels, 2; paresthesia, 2; folliculitis, 1; moniliasis, 1; bacterial infection; 1 skin depigmentation, 1. The following signs of skin atrophy were also observed among 97 subjects treated with mometasone furoate cream 0.1% in a clinical trial: shininess, 4; telangiectasia, 1; loss of elasticity, 4; loss of normal skin markings, 4; thinness, 1; and bruising, 1.
6.2 Postmarketing Experience
Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Postmarketing reports for local adverse reactions to topical corticosteroids include irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, and miliaria. These adverse reactions may occur more frequently with the use of occlusive dressings.
Postmarketing reports for ophthalmic adverse reactions to topical corticosteroids include blurred vision, cataracts, glaucoma, increased intraocular pressure, and central serous chorioretinopathy.
To report SUSPECTED ADVERSE REACTIONS, contact G&W Laboratories, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
7 DRUG INTERACTIONS
No drug-drug interaction studies have been conducted with mometasone furoate cream 0.1%.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Teratogenic Effects Pregnancy Category C:
There are no adequate and well-controlled studies in pregnant women. Therefore, mometasone furoate cream 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
When administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. The doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. Mometasone furoate also caused dystocia and related complications when administered to rats during the end of pregnancy.
In mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above. Fetal survival was reduced at 180 mcg/kg. No toxicity was observed at 20 mcg/kg. (Doses of 20, 60, and 180 mcg/kg in the mouse are approximately 0.01, 0.02, and 0.05 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m2 basis.)
In rats, mometasone furoate produced umbilical hernias at topical doses of 600 mcg/kg and above. A dose of 300 mcg/kg produced delays in ossification, but no malformations. (Doses of 300 and 600 mcg/kg in the rat are approximately 0.2 and 0.4 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m2 basis.)
In rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at topical doses of 150 mcg/kg and above (approximately 0.2 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m2 basis). In an oral study, mometasone furoate increased resorptions and caused cleft palate and/or head malformations (hydrocephaly and domed head) at 700 mcg/kg. At 2800 mcg/kg most litters were aborted or resorbed. No toxicity was observed at 140 mcg/kg. (Doses at 140, 700, and 2800 mcg/kg in the rabbit are approximately 0.2, 0.9, and 3.6 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m2 basis.)
When rats received subcutaneous doses of mometasone furoate throughout pregnancy or during the later stages of pregnancy, 15 mcg/kg caused prolonged and difficult labor and reduced the number of live births, birth weight, and early pup survival. Similar effects were not observed at 7.5 mcg/kg. (Doses of 7.5 and 15 mcg/kg in the rat are approximately 0.005 and 0.01 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m2 basis.)
8.3 Nursing Mothers
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when mometasone furoate cream 0.1% is administered to a nursing woman.
8.4 Pediatric Use
Mometasone furoate cream 0.1% may be used with caution in pediatric patients 2 years of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established. Since safety and efficacy of mometasone furoate cream 0.1% have not been established in pediatric patients below 2 years of age, its use in this age group is not recommended.
In a pediatric trial, 24 atopic dermatitis subjects, of whom 19 subjects were age 2 to 12 years, were treated with mometasone furoate cream 0.1% once daily. The majority of subjects cleared within 3 weeks. Mometasone furoate cream 0.1% caused HPA axis suppression in approximately 16% of pediatric subjects ages 6 to 23 months, who showed normal adrenal function by Cortrosyn test before starting treatment, and were treated for approximately 3 weeks over a mean body surface area of 41% (range 15%-94%). The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after trial completion, available for 5 of the subjects, demonstrated suppressed HPA axis function in 1 subject, using these same criteria. Long-term use of topical corticosteroids has not been studied in this population [see Clinical Pharmacology (12.2) ].
Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are, therefore, also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical corticosteroids. Pediatric patients applying topical corticosteroids to greater than 20% of body surface are at higher risk of HPA axis suppression.
HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Mometasone furoate cream 0.1% should not be used in the treatment of diaper dermatitis.
8.5 Geriatric Use
Clinical studies of mometasone furoate cream 0.1% included 190 subjects who were 65 years of age and over and 39 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.
10 OVERDOSAGE
Topically applied mometasone furoate cream 0.1% can be absorbed in sufficient amounts to produce systemic effects [see Warnings and Precautions (5.1) ].
11 DESCRIPTION
Mometasone furoate cream 0.1% contains mometasone furoate for topical use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.
Chemically, mometasone furoate is 9α,21-dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2- furoate), with the empirical formula C27H30Cl2O6, a molecular weight of 521.4 and the following structural formula:
Mometasone furoate is a white to off-white powder practically insoluble in water, slightly soluble in octanol, and moderately soluble in ethyl alcohol.
Each gram of mometasone furoate cream 0.1% contains 1 mg mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Like other topical corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
12.2 Pharmacodynamics
Studies performed with mometasone furoate cream 0.1% indicate that it is in the medium range of potency as compared with other topical corticosteroids.
In a study evaluating the effects of mometasone furoate cream on the HPA axis, 15 grams were applied twice daily for 7 days to six adult subjects with psoriasis or atopic dermatitis. The cream was applied without occlusion to at least 30% of the body surface. The results showed that the drug caused a slight lowering of adrenal corticosteroid secretion [see Warnings and Precautions (5.1) ].
Ninety-seven pediatric subjects ages 6 to 23 months with atopic dermatitis, were enrolled in an open-label, HPA axis safety study. Mometasone furoate cream 0.1% was applied once daily for approximately 3 weeks over a mean body surface area of 41% (range 15%-94%). In approximately 16% of subjects who showed normal adrenal function by Cortrosyn test before starting treatment, adrenal suppression was observed at the end of treatment with mometasone furoate cream 0.1%. The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 5 of the subjects, demonstrated suppressed HPA axis function in one subject, using these same criteria [see Use in Specific Populations (8.4) ].
12.3 Pharmacokinetics
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Studies in humans indicate that approximately 0.4% of the applied dose of mometasone furoate cream 0.1% enters the circulation after 8 hours of contact on normal skin without occlusion. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term animal studies have not been performed to evaluate the carcinogenic potential of mometasone furoate cream 0.1%. Long-term carcinogenicity studies of mometasone furoate were conducted by the inhalation route in rats and mice. In a 2-year carcinogenicity study in Sprague Dawley rats, mometasone furoate demonstrated no statistically significant increase of tumors at inhalation doses up to 67 mcg/kg (approximately 0.04 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m2 basis). In a 19-month carcinogenicity study in Swiss CD-1 mice, mometasone furoate demonstrated no statistically significant increase in the incidence of tumors at inhalation doses up to 160 mcg/kg (approximately 0.05 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m 2 basis).
Mometasone furoate increased chromosomal aberrations in an in vitro Chinese hamster ovary cell assay, but did not increase chromosomal aberrations in an in vitro Chinese hamster lung cell assay. Mometasone furoate was not mutagenic in the Ames test or mouse lymphoma assay, and was not clastogenic in an in vivo mouse micronucleus assay, a rat bone marrow chromosomal aberration assay, or a mouse male germ-cell chromosomal aberration assay. Mometasone furoate also did not induce unscheduled DNA synthesis in vivo in rat hepatocytes.
In reproductive studies in rats, impairment of fertility was not produced in male or female rats by subcutaneous doses up to 15 mcg/kg (approximately 0.01 times the estimated maximum clinical topical dose from mometasone furoate cream 0.1% on a mcg/m2 basis).
14 CLINICAL STUDIES
The safety and efficacy of the mometasone furoate cream 0.1% for the treatment of corticosteroid-responsive dermatoses were evaluated in two randomized, double-blind, vehicle-controlled clinical trials, one in psoriasis and one in atopic dermatitis. A total 366 subjects (12-81 years of age), of whom 177 received mometasone furoate cream 0.1% and 181 subjects received vehicle cream, were evaluated in these trials. Mometasone furoate cream 0.1% or the vehicle cream were applied once daily for 21 days.
The two trials showed mometasone furoate cream 0.1% is effective in the treatment of psoriasis and atopic dermatitis.
16 HOW SUPPLIED/STORAGE AND HANDLING
Mometasone furoate cream 0.1% is supplied in 15 g (0713-0634-15) and 45 g (NDC: 0713-0634-37) tubes; boxes of one.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Avoid excessive heat.
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information). Inform patients of the following:
Use mometasone furoate cream 0.1% as directed by the physician. It is for external use only.
Avoid contact with the eyes.
Advise patients to report any visual symptoms to their healthcare providers.
Do not use mometasone furoate cream 0.1% on the face, underarms, or groin areas unless directed by the physician.
Do not use mometasone furoate cream 0.1% for any disorder other than that for which it was prescribed.
Do not bandage or otherwise cover or wrap the treated skin area so as to be occlusive, unless directed by the physician.
Report any signs of local adverse reactions to the physician.
Advise patients not to use mometasone furoate cream 0.1% in the treatment of diaper dermatitis. Do not apply mometasone furoate cream 0.1% in the diaper area, as diapers or plastic pants may constitute occlusive dressing.
Discontinue therapy when control is achieved. If no improvement is seen within 2 weeks, contact the physician.
Do not use other corticosteroid-containing products with mometasone furoate cream 0.1% without first consulting with the physician.
Patient Information
Mometasone Furoate Cream 0.1%
(Mo-meta-sone fur-o-ate)
Important information: Mometasone Furoate Cream 0.1% is for use on skin only. Do not use mometasone furoate cream 0.1% in your eyes, mouth, or vagina.
What is mometasone furoate cream 0.1%?
Mometasone furoate cream 0.1% is a prescription medicine used on the skin (topical) for the relief of redness, swelling, heat, pain (inflammation) and itching, caused by certain skin problems in people 2 years of age and older.
It is not known if mometasone furoate cream 0.1% is safe and effective for use in children under 2 years of age.
Mometasone furoate cream 0.1% should not be used in children under 2 years of age.
It is not known if mometasone furoate cream 0.1% is safe and effective for use in children longer than 3 weeks.
Do not use mometasone furoate cream 0.1% if you are allergic to mometasone furoate or any of the ingredients in mometasone furoate cream 0.1%. See the end of this leaflet for a complete list of ingredients in mometasone furoate cream 0.1%.
Before using mometasone furoate cream 0.1%, tell your healthcare provider about all your medical conditions, including if you:
have a skin infection at the site to be treated. You may also need medicine to treat the skin infection.
are pregnant or plan to become pregnant. It is not known if mometasone furoate cream 0.1% will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if mometasone furoate cream 0.1% passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Especially tell your healthcare provider if you take other corticosteroid medicines by mouth or use other products on your skin or scalp that contain corticosteroids.
How should I use mometasone furoate cream 0.1%?
Use mometasone furoate cream 0.1% exactly as your healthcare provider tells you to use it.
Apply a thin film of mometasone furoate cream 0.1% to the affected skin area 1 time each day.
Tell your healthcare provider if the treated skin area does not get better after 2 weeks of treatment.
Do not bandage, cover, or wrap the treated skin area unless your healthcare provider tells you to.
Mometasone furoate cream 0.1% should not be used to treat diaper rash or redness. Do not apply mometasone furoate cream 0.1% in the diaper area if wearing diapers or plastic pants.
Avoid using mometasone furoate cream 0.1% on the face, groin, or underarms (armpits).
Wash your hands after applying mometasone furoate cream 0.1%.
What are the possible side effects of mometasone furoate cream 0.1%?
Mometasone furoate cream 0.1% may cause serious side effects, including:
Mometasone furoate cream 0.1% can pass through your skin. Too much mometasone furoate cream 0.1% passing through your skin can cause your adrenal glands to stop working properly. Your healthcare provider may do blood tests to check for adrenal gland problems.
Vision problems. Topical corticosteroids may increase your chance of developing vision problems such as cataract and glaucoma. Tell your healthcare provider if you develop blurred vision or other vision problems during treatment with mometasone furoate cream 0.1%.
Skin problems. Skin problems may happen during treatment with mometasone furoate cream 0.1%, including allergic reactions (contact dermatitis) and skin infections at the treatment site. Stop using mometasone furoate cream 0.1% and tell your healthcare provider if you develop any skin reactions such as pain, tenderness, swelling, or problems healing during treatment with mometasone furoate cream 0.1%.
The most common side effects of mometasone furoate cream 0.1% include burning, itching, and thinning of the skin (atrophy).
These are not all the possible side effects of mometasone furoate cream 0.1%.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store mometasone furoate cream 0.1%?
Store mometasone furoate cream 0.1% at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Avoid excessive heat.
Keep mometasone furoate cream 0.1% and all medicines out of the reach of children.
General information about the safe and effective use of mometasone furoate cream 0.1%.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use mometasone furoate cream 0.1% for a condition for which it was not prescribed. Do not give mometasone furoate cream 0.1% to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about mometasone furoate cream 0.1% that is written for health professionals.
What are the ingredients in mometasone furoate cream 0.1%?
Active ingredient: mometasone furoate
Inactive ingredients: hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch ocetnylsuccinate, white wax, white petrolatum, and purified water.
Manufactured by:
G&W Laboratories, Inc.
111 Coolidge Street
South Plainfield, NJ 07080
8-0634GW4
Rev. 06/2018
This Patient Information has been approved by the U.S. Food and Drug Administration.
Mometasone Furoate packaging
NDC: 0713-0634-15
15 g carton (Note: the 45 g carton is the product actually included in this kit)
| QUINOSONE
mometasone furoate and ammonium lactate kit |
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Labeler - V2 Pharma, LLC (102457346) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Taro Pharmaceuticals Inc. | 206263295 | MANUFACTURE(51672-1300) | |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| G&W Laboratories, Inc. | 079763718 | analysis(0713-0634) , manufacture(0713-0634) , label(0713-0634) , pack(0713-0634) | |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| V2 Pharma, LLC | 102457346 | relabel(72835-301) | |